A Genes-to-Molecules Platform for Expanding Natural Product Diversity
A Genes-to-Molecules Platform for Expanding Natural Product Diversity
批准号:
9918085
负责人:
Mark J Burk
金额:
$22.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2022-06-30
关键词:
AlgorithmsAnabolismBinding SitesBioinformaticsBiologicalBiological AssayCellsChemicalsCloningCollaborationsCollectionComplementCoupledCustomDNADNA biosynthesisDataData SetDatabasesDepositionDevelopmentEnzymesFDA approvedFamilyGenbankGene ClusterGenerationsGenesGenetic TranscriptionGenomeGenomicsGoalsHourIllinoisIn VitroIndustrializationInstitutesInvestigationJointsLassoLibrariesMetagenomicsMethodsMiningMolecularNatural ProductsNatural ResourcesNaturePathway interactionsPeptide BiosynthesisPeptidesPharmaceutical PreparationsPhaseProductionPublishingReportingRibosomesRoboticsSmall Business Technology Transfer ResearchSourceSpeedSystemTechniquesTechnologyTherapeuticTimeTracerTranslatingTranslationsUniversitiesWorkantimicrobialbasecostdata miningdrug developmentdrug discoveryhigh throughput technologyimprovedin silicoinnovationinterestmetagenomenext generation sequencingnovelnovel diagnosticspeptide analogphase 1 studyprogramsprotein aminoacid sequencescreening
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug
discovery and development. Over the past 30 years, NP-derived drugs have accounted for more
than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs
has slowed over the past 15 years due to the lack of efficient methods for discovery, production,
and optimization, coupled with the high rate of NP rediscovery using traditional bioassay-guided
isolation techniques. Recently, next generation sequencing and genome-mining algorithms
suggest that a wealth of uncharacterized natural products exist in Nature, revealing a vast
untapped source of chemical diversity and biological activity. To unlock the latent potential of NPs
predicted from genome-mining, our proposed Phase I study aims to develop an integrated high-
throughput (HT) technology platform for rapidly (1) identifying, (2) synthesizing, and (3) screening
new NPs. In Phase II, this technology platform will be automated with robotics to provide
unprecedented speed and throughput for NP discovery and optimization.
The utility of this integrated platform first will be demonstrated during Phase I using lasso peptides
as a representative NP class. Lasso peptides are ribosomally synthesized and post translationally
modified peptides (RiPPs) that display a unique folded topology that endows the compounds with
extraordinary stability and a myriad of promising biological activities. The aim of this proposal is
to develop a platform that will significantly expand the known repertoire of lasso peptides, analogs,
and targets. Genomic and metagenomic data mining will provide the sequence information
required for HT generation of lasso peptides that will be screened for biological activity (initially
antimicrobial). The proposed specific aims outlined below will be achieved through the
collaboration between Genomatica, Inc. and Dr. Douglas Mitchell at the University of Illinois at
Urbana-Champaign.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1021/jacs.1c01452
发表时间:
2021-04-21
期刊:
Journal of the American Chemical Society
影响因子:
15
作者:
[Si Y, Kretsch AM, Daigh LM, Burk MJ, Mitchell DA]
通讯作者:
Mitchell DA
Development of Lasso Peptides as Potent Endothelin Receptor B Antagonists for Immuno-oncology
-
批准号:10259206
-
项目类别:
-
资助金额:$39.96万
-
财政年份:2021
-
负责人:Mark J Burk
-
依托单位:
海外基金